Idebenone Exerts anti-Triple Negative Breast Cancer Effects via Dual Signaling Pathways of GADD45 and AMPK

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98. doi:10.1158/2159-8290.CD-18-1177.
   PubMed Web of Science ®Google Scholar
• Klopstock T, Priglinger C, Yilmaz A, Kornblum C, Distelmaier F, Prokisch H. Mitochondrial disorders. Dtsch Arztebl Int. 2021;118(44):741–8. doi:10.3238/arztebl.m2021.0251.
   PubMed Web of Science ®Google Scholar
• Tonon C, Lodi R. Idebenone in Friedreich’s ataxia. Expert Opin Pharmacother. 2008;9(13):2327–37. doi:10.1517/14656566.9.13.2327.
   PubMed Web of Science ®Google Scholar
• Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagrèze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, et al. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. J Neuroophthalmol. 2017;37(4):371–81. doi:10.1097/WNO.0000000000000570.
   PubMed Web of Science ®Google Scholar
• Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, Castillo L, Friedburg C, Halfpenny CA, Lincoln JA, et al. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol. 2020;40(4):558–65. doi:10.1097/WNO.0000000000001023.
   PubMed Web of Science ®Google Scholar
• Shieh PB. Emerging strategies in the treatment of duchenne muscular dystrophy. Neurotherapeutics. 2018;15(4):840–8. doi:10.1007/s13311-018-00687-z.
   PubMed Web of Science ®Google Scholar
• Tai KK, Pham L, Truong DD. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res. 2011;20(4):321–8. doi:10.1007/s12640-011-9245-z.
   PubMed Web of Science ®Google Scholar
• Damiani E, Yuecel R, Wallace HM. Repurposing of idebenone as a potential anti-cancer agent. Biochem J. 2019;476(2):245–59. doi:10.1042/BCJ20180384.
   PubMedGoogle Scholar
• Seo Y, Park J, Kim M, Lee HK, Kim JH, Jeong JH, Namkung W. Inhibition of ANO1/TMEM16A chloride channel by idebenone and its cytotoxicity to cancer cell lines. PLoS One. 2015;10(7):e0133656. doi:10.1371/journal.pone.0133656.
   PubMed Web of Science ®Google Scholar
• Green DR, Llambi F. Cell death signaling. Cold Spring Harb Perspect Biol. 2015;7(12):a006080. doi:10.1101/cshperspect.a006080.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim Y, Lee S-B, Oh CW, Lee EJ, Ko JY, Park JH. Autophagy inhibits cancer stemness in triple-negative breast cancer via miR-181a-mediated regulation of ATG5 and/or ATG2B. Mol Oncol. 2022;16(9):1857–75. doi:10.1002/1878-0261.13180.
   PubMed Web of Science ®Google Scholar
• Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T. The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol. 2023;24(3):167–85. doi:10.1038/s41580-022-00542-2.
   PubMed Web of Science ®Google Scholar
• Li W, He P, Huang Y, Li Y-F, Lu J, Li M, Kurihara H, Luo Z, Meng T, Onishi M, et al. Selective autophagy of intracellular organelles: recent research advances. Theranostics. 2021;11(1):222–56. doi:10.7150/thno.49860.
   PubMed Web of Science ®Google Scholar
• Feng H, Cheng X, Kuang J, Chen L, Yuen S, Shi M, Liang J, Shen B, Jin Z, Yan J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 2018;9(10):1030. doi:10.1038/s41419-018-1054-3.
   PubMedGoogle Scholar
• Ahmed SA, Mendonca P, Elhag R, Soliman KFA. Anticancer effects of fucoxanthin through cell cycle arrest, apoptosis induction, angiogenesis inhibition, and autophagy modulation. Int J Mol Sci. 2022;23(24):16091. doi:10.3390/ijms232416091.
   PubMed Web of Science ®Google Scholar
• Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021;26(9–10):512–33. doi:10.1007/s10495-021-01687-9.
   PubMed Web of Science ®Google Scholar
• Paglin S, Lee N-Y, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res. 2005;65(23):11061–70. doi:10.1158/0008-5472.CAN-05-1083.
   PubMed Web of Science ®Google Scholar
• Wang W, Jiang J, Huang Y, Peng F, Hu T, Wu J, Pan X, Rao C. Aconitine induces autophagy via activating oxidative DNA damage-mediated AMPK/ULK1 signaling pathway in H9c2 cells. J Ethnopharmacol. 2022;282:114631. doi:10.1016/j.jep.2021.114631.
   PubMed Web of Science ®Google Scholar
• Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 2015;356(2 Pt A):165–70. doi:10.1016/j.canlet.2014.01.018.
   PubMed Web of Science ®Google Scholar
• Ponnusamy L, Natarajan SR, Thangaraj K, Manoharan R. Therapeutic aspects of AMPK in breast cancer: progress, challenges, and future directions. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188379. doi:10.1016/j.bbcan.2020.188379.
   PubMed Web of Science ®Google Scholar
• Al-Maghrabi J, Al-Sakkaf K, Qureshi IA, Butt NS, Damnhory L, Elshal M, Al-Maghrabi B, Aldahlawi A, Ashoor S, Brown B, et al. AMPK expression patterns are significantly associated with poor prognosis in breast cancer patients. Ann Diagn Pathol. 2017;29:62–7. doi:10.1016/j.anndiagpath.2017.05.012.
   PubMed Web of Science ®Google Scholar
• Ma Z-J, Lu L, Yang J-J, Wang X-X, Su G, Wang Z-L, Chen G-H, Sun H-M, Wang M-Y, Yang Y. Lariciresinol induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway. Eur J Pharmacol. 2018;821:1–10. doi:10.1016/j.ejphar.2017.12.027.
   PubMed Web of Science ®Google Scholar
• Noda T, Fujita N, Yoshimori T. The late stages of autophagy: how does the end begin? Cell Death Differ. 2009;16(7):984–90. doi:10.1038/cdd.2009.54.
   PubMed Web of Science ®Google Scholar
• Tomilov A, Allen S, Hui CK, Bettaieb A, Cortopassi G. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res. 2018;137:89–103. doi:10.1016/j.phrs.2018.09.024.
   PubMed Web of Science ®Google Scholar
• Wright KD, Miller BS, El-Meanawy S, Tsaih S-W, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H, et al. The p52 isoform of SHC1 is a key driver of breast cancer initiation. Breast Cancer Res. 2019;21(1):74. doi:10.1186/s13058-019-1155-7.
   PubMedGoogle Scholar
• Acevedo-Díaz A, Morales-Cabán BM, Zayas-Santiago A, Martínez-Montemayor MM, Suárez-Arroyo IJ. SCAMP3 regulates EGFR and promotes proliferation and migration of triple-negative breast cancer cells through the modulation of AKT, ERK, and STAT3 signaling pathways. Cancers (Basel). 2022;14(11):2807. doi:10.3390/cancers14112807.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, Huang J, Chen Y, Wang X, Sun J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12(10):4564–80. doi:10.7150/thno.68972.
   PubMed Web of Science ®Google Scholar
• Liu K, Zheng M, Lu R, Du J, Zhao Q, Li Z, Li Y, Zhang S. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell Int. 2020;20(1):213. doi:10.1186/s12935-020-01304-w.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803–15. doi:10.1038/sj.onc.1204252.
   PubMed Web of Science ®Google Scholar
• Qi R, Wang J, Jiang Y, Qiu Y, Xu M, Rong R, Zhu T. Snai1-induced partial epithelial-mesenchymal transition orchestrates p53-p21-mediated G2/M arrest in the progression of renal fibrosis via NF-κB-mediated inflammation. Cell Death Dis. 2021;12(1):44. doi:10.1038/s41419-020-03322-y.
   PubMed Web of Science ®Google Scholar
• Mo Q, Xu K, Luo C, Zhang Q, Wang L, Ren G. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. Biochem Biophys Res Commun. 2021;553:17–24. doi:10.1016/j.bbrc.2021.03.022.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–14. doi:10.1038/nrc2657.
   PubMed Web of Science ®Google Scholar
• Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B, Fotedar R, Fotedar A. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell. 2005;17(2):237–49. doi:10.1016/j.molcel.2004.11.049.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Huang TY, Chen MJ. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014;5(4):e1198–e1198. doi:10.1038/cddis.2014.151.
   PubMedGoogle Scholar
• Zolotovskaia MA, Modestov AA, Suntsova MV, Rachkova AA, Koroleva EV, Poddubskaya EV, Sekacheva MI, Tkachev VS, Garazha AV, Glusker AA, et al. Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways. DNA Repair (Amst). 2023;123:103448. doi:10.1016/j.dnarep.2023.103448.
   PubMed Web of Science ®Google Scholar
• Yan J, Sun W, Shen M, Zhang Y, Jiang M, Liu A, Ma H, Lai X, Wu J. Idebenone improves motor dysfunction, learning and memory by regulating mitophagy in MPTP-treated mice. Cell Death Discov. 2022;8(1):28. doi:10.1038/s41420-022-00826-8.
   PubMed Web of Science ®Google Scholar
• Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121–35. doi:10.1038/nrm.2017.95.
   PubMed Web of Science ®Google Scholar
• Löffler AS, Alers S, Dieterle AM, Keppeler H, Franz-Wachtel M, Kundu M, Campbell DG, Wesselborg S, Alessi DR, Stork B. Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. Autophagy. 2011;7(7):696–706. doi:10.4161/auto.7.7.15451.
   PubMed Web of Science ®Google Scholar
• Qiu J, Xue X, Hu C, Xu H, Kou D, Li R, Li M. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer. 2016;7(2):167–73. doi:10.7150/jca.10944.
   PubMed Web of Science ®Google Scholar
• Wein L, Loi S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast. 2017;34 Suppl 1(Suppl 1):S27–S30. doi:10.1016/j.breast.2017.06.023.
   PubMedGoogle Scholar
• Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879–93.e13. doi:10.1016/j.cell.2018.03.041.
   PubMed Web of Science ®Google Scholar
• Huang S. mTOR signaling in metabolism and cancer. Cells. 2020;9(10):2278. doi:10.3390/cells9102278.
   PubMed Web of Science ®Google Scholar
• Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin. 2020;41(11):1403–9. doi:10.1038/s41401-020-00508-0.
   PubMed Web of Science ®Google Scholar
• Ren G, Ma Y, Wang X, Zheng Z, Li G. Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. Eur J Pharmacol. 2022;932:175208. doi:10.1016/j.ejphar.2022.175208.
   PubMed Web of Science ®Google Scholar
• Chou C-C, Lee K-H, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen C-S. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res. 2014;74(17):4783–95. doi:10.1158/0008-5472.CAN-14-0135.
   PubMed Web of Science ®Google Scholar
• Fumarola C, Caffarra C, La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Galvani E, Generali D, Petronini PG, Bonelli MA. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res Treat. 2013;141(1):67–78. doi:10.1007/s10549-013-2668-x.
   PubMed Web of Science ®Google Scholar
• Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, et al. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. Breast. 2019;45:22–8. doi:10.1016/j.breast.2019.02.002.
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Sumner CJ, Penzak SR, Ravina B, Fischbeck KH, Taylor JP. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol. 2007;64(6):803–8. doi:10.1001/archneur.64.6.803.
   PubMedGoogle Scholar
• Gewirtz DA. The switch between protective and nonprotective autophagy; implications for autophagy inhibition as a therapeutic strategy in cancer. Biology (Basel). 2020;9(1). doi:10.3390/biology9010012.
   PubMedGoogle Scholar
• Tailor D, Going CC, Resendez A, Kumar V, Nambiar DK, Li Y, Dheeraj A, LaGory EL, Ghoochani A, Birk AM, et al. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. Br J Cancer. 2021;124(3):604–15. doi:10.1038/s41416-020-01137-4.
   PubMed Web of Science ®Google Scholar